FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143048500> ?p ?o ?g. }

• W2143048500 endingPage "1040" @default.
• W2143048500 startingPage "1030" @default.
• W2143048500 abstract "Background. Rifapentine administered 5 days per week has potent activity in mouse models of antituberculosis chemotherapy, but efficacy and safety data are limited in humans. We compared the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment. Methods. In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase. Results. Negative cultures on solid media occurred in 145 of 174 participants (83.3%) in the rifampin group and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence interval [CI]: − 4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1%) in the rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: −6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P = .79). Conclusions. The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted. Clinical Trials registration. NCT00694629." @default.
• W2143048500 created "2016-06-24" @default.
• W2143048500 creator A5000425322 @default.
• W2143048500 creator A5008442458 @default.
• W2143048500 creator A5012290228 @default.
• W2143048500 creator A5012638474 @default.
• W2143048500 creator A5013628607 @default.
• W2143048500 creator A5017664264 @default.
• W2143048500 creator A5018111646 @default.
• W2143048500 creator A5023434139 @default.
• W2143048500 creator A5034410442 @default.
• W2143048500 creator A5048965341 @default.
• W2143048500 creator A5049700288 @default.
• W2143048500 creator A5051986256 @default.
• W2143048500 creator A5054997173 @default.
• W2143048500 creator A5058077155 @default.
• W2143048500 creator A5062831296 @default.
• W2143048500 creator A5065032010 @default.
• W2143048500 creator A5068140387 @default.
• W2143048500 creator A5078598988 @default.
• W2143048500 date "2012-07-30" @default.
• W2143048500 modified "2023-10-10" @default.
• W2143048500 title "Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium" @default.
• W2143048500 cites W104155408 @default.
• W2143048500 cites W117549336 @default.
• W2143048500 cites W1970189825 @default.
• W2143048500 cites W1974598076 @default.
• W2143048500 cites W1991360918 @default.
• W2143048500 cites W1991957921 @default.
• W2143048500 cites W2008916602 @default.
• W2143048500 cites W2047509792 @default.
• W2143048500 cites W2047701762 @default.
• W2143048500 cites W2072475014 @default.
• W2143048500 cites W2077195266 @default.
• W2143048500 cites W2089663335 @default.
• W2143048500 cites W2096015848 @default.
• W2143048500 cites W2096913021 @default.
• W2143048500 cites W2099498194 @default.
• W2143048500 cites W2125547281 @default.
• W2143048500 cites W2134490126 @default.
• W2143048500 cites W2134527984 @default.
• W2143048500 cites W2139696962 @default.
• W2143048500 cites W2152562731 @default.
• W2143048500 cites W2159717558 @default.
• W2143048500 cites W2169203610 @default.
• W2143048500 cites W2418210342 @default.
• W2143048500 cites W4242879591 @default.
• W2143048500 cites W4251330017 @default.
• W2143048500 doi "https://doi.org/10.1093/infdis/jis461" @default.
• W2143048500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22850121" @default.
• W2143048500 hasPublicationYear "2012" @default.
• W2143048500 type Work @default.
• W2143048500 sameAs 2143048500 @default.
• W2143048500 citedByCount "95" @default.
• W2143048500 countsByYear W21430485002012 @default.
• W2143048500 countsByYear W21430485002013 @default.
• W2143048500 countsByYear W21430485002014 @default.
• W2143048500 countsByYear W21430485002015 @default.
• W2143048500 countsByYear W21430485002016 @default.
• W2143048500 countsByYear W21430485002017 @default.
• W2143048500 countsByYear W21430485002018 @default.
• W2143048500 countsByYear W21430485002019 @default.
• W2143048500 countsByYear W21430485002020 @default.
• W2143048500 countsByYear W21430485002021 @default.
• W2143048500 countsByYear W21430485002022 @default.
• W2143048500 countsByYear W21430485002023 @default.
• W2143048500 crossrefType "journal-article" @default.
• W2143048500 hasAuthorship W2143048500A5000425322 @default.
• W2143048500 hasAuthorship W2143048500A5008442458 @default.
• W2143048500 hasAuthorship W2143048500A5012290228 @default.
• W2143048500 hasAuthorship W2143048500A5012638474 @default.
• W2143048500 hasAuthorship W2143048500A5013628607 @default.
• W2143048500 hasAuthorship W2143048500A5017664264 @default.
• W2143048500 hasAuthorship W2143048500A5018111646 @default.
• W2143048500 hasAuthorship W2143048500A5023434139 @default.
• W2143048500 hasAuthorship W2143048500A5034410442 @default.
• W2143048500 hasAuthorship W2143048500A5048965341 @default.
• W2143048500 hasAuthorship W2143048500A5049700288 @default.
• W2143048500 hasAuthorship W2143048500A5051986256 @default.
• W2143048500 hasAuthorship W2143048500A5054997173 @default.
• W2143048500 hasAuthorship W2143048500A5058077155 @default.
• W2143048500 hasAuthorship W2143048500A5062831296 @default.
• W2143048500 hasAuthorship W2143048500A5065032010 @default.
• W2143048500 hasAuthorship W2143048500A5068140387 @default.
• W2143048500 hasAuthorship W2143048500A5078598988 @default.
• W2143048500 hasBestOaLocation W21430485001 @default.
• W2143048500 hasConcept C126322002 @default.
• W2143048500 hasConcept C141071460 @default.
• W2143048500 hasConcept C142724271 @default.
• W2143048500 hasConcept C2776228421 @default.
• W2143048500 hasConcept C2776301714 @default.
• W2143048500 hasConcept C2776306059 @default.
• W2143048500 hasConcept C2776967927 @default.
• W2143048500 hasConcept C2776991065 @default.
• W2143048500 hasConcept C2777768864 @default.
• W2143048500 hasConcept C2777975735 @default.
• W2143048500 hasConcept C2779806340 @default.
• W2143048500 hasConcept C2779912665 @default.

• next